Dashboard
Manage Tickers

ENTX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
08/12/2024 10:55:24

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

entera-bio-q2-eps-006-inline-sales-5700k
Entera Bio Q2 EPS $(0.06), Inline, Sales $...
08/09/2024 20:09:11

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 62....

entera-to-present-eb613-once-daily-pth1-34-tablet-treatment-dedicated-to-post-menopausal-women-with-high-risk-osteoporosis-abstract-at-the-asbmr-2024-annual-meeting-key-sabre-update-also-expected
Entera To Present EB613, Once Daily PTH(1-...
08/01/2024 12:40:42

Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered pept...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
06/05/2024 11:02:57

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

entera-bio-presents-phase-1-clinical-data-of-oral-pth1-34-peptide-candidate-eb612-for-patients-with-hypoparathyroidism-at-endo-2024
Entera Bio Presents Phase 1 Clinical Data ...
06/03/2024 12:14:35

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
05/14/2024 10:31:40

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
05/13/2024 11:58:21

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

entera-bio-q1-eps-005-beats-006-estimate
Entera Bio Q1 EPS $(0.05) Beats $(0.06) Es...
05/10/2024 20:18:23

Entera Bio (NASDAQ: ENTX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) b...

entera-bio-announces-publication-of-oral-pth1-34-peptide-tablets-eb613-phase-2-trial-data-i1n-the-journal-of-bone-and-mineral-research
Entera Bio Announces Publication Of Oral P...
04/08/2024 12:33:29

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

hc-wainwright--co-maintains-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Maintains Buy on Enter...
04/02/2024 12:54:27

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price tar...

entera-bio-announces-key-regulatory-milestone-for-oral-pth1-34-peptide-eb613-phase-3-program-fda-ruling-on-qualifying-bmd-as-a-surrogate-endpoint-for-osteoporosis-drugs-is-expected-within-10-months
Entera Bio Announces Key Regulatory Milest...
03/26/2024 12:33:46

Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered pept...

entera-bio-announces-pharmacokinetic-data-for-oral-glp-2-peptide-tablet-treatment-for-patients-with-short-bowel-syndrome-says-the-studys-objectives-were-met-with-oral-glp-2-tablets-exhibiting-significant-systemic-exposure
Entera Bio Announces Pharmacokinetic Data ...
03/20/2024 12:03:25

entera-bio-fy23-eps-031-vs-041-yoy-as-of-december-31-2023-entera-had-cash-and-cash-equivalents-of-110m
Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY...
03/08/2024 21:17:40

Financial Results for the year Ended December 31, 2023As of December 31, 2023, Entera had cash and cash equivalents of $11.0 mi...

entera-bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement
Entera Bio Regains Compliance With Nasdaq ...
03/04/2024 13:47:35

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

entera-bio-and-3-other-stocks-under-1-insiders-are-buying
Entera Bio And 3 Other Stocks Under $1 Ins...
01/12/2024 12:48:34

The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or...

entera-bio-announced-that-it-received-an-extension-of-180-calendar-days-from-the-nasdaq-stock-market-to-regain-compliance
Entera Bio Announced That It Received An E...
01/03/2024 13:49:28

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
12/11/2023 11:42:24

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

interim-results-from-ongoing-clinical-study-confirm-eb613-optimized-profile-for-osteoporosis-treatment-and-potential-for-enteras-next-generation-oral-peptide-platform
Interim Results From Ongoing Clinical Stud...
11/29/2023 13:33:37

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

entera-bio-reports-rapid-pharmacodynamic-response-and-consistent-pharmacokinetic-data-for-its-first-in-class-oral-pth1-34-mini-tablets-at-the-asbmr-2023-annual-meeting
Entera Bio Reports Rapid Pharmacodynamic R...
10/16/2023 12:20:22

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
09/13/2023 10:33:06

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION